Quality of life in a clinical trial of highly active antiretroviral therapy alone or with intravenous or subcutaneous interleukin-2 administration

Article Abstract:

Health-related quality of life (HRQOL) outcomes in a randomized clinical trial sponsored by the adult aids Clinical Trials Group (aaCTG) of the National Institutes of Health, aaCTG Protocol 328 that was assessed is described. Evidence of a short-term but not long-term adverse impact of interleukin-2 on HRQOL and some evidence on long term benefit for the subcutaneous group are found.

Patient outcomes, Drug therapy, Dosage and administration, Interleukin-2, Highly active antiretroviral therapy

---

Gene therapy of HIV infection by transduced autologous CD4 T-cells inhibiting viral entry

Article Abstract:

Data on the preclinical development strategy for a novel gene therapy approach mediated by transduced autologus CD4 T-cells were presented. A positive relation between the absolute number of transfected CD4 T-cells and increases of CD4 counts was observed.

United States, Health aspects, Care and treatment, Gene therapy, CD4 lymphocytes

---

Similar abstracts:

• Abstracts: Daily low-dose subcutaneous interleukin-2 added to single- or dual- nucleoside therapy in HIV infection does not protect against CD4 (super +) T-cell decline or improve other indices of immune function: results of a randomized controlled clinical trial
• Abstracts: Antihypertensive treatment based on conventional or ambulatory blood pressure measurement: a randomized controlled trial

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.